These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36509938)

  • 1. Ozoralizumab: First Approval.
    Keam SJ
    Drugs; 2023 Jan; 83(1):87-92. PubMed ID: 36509938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ozoralizumab, a Humanized Anti-TNFα NANOBODY
    Ishiwatari-Ogata C; Kyuuma M; Ogata H; Yamakawa M; Iwata K; Ochi M; Hori M; Miyata N; Fujii Y
    Front Immunol; 2022; 13():853008. PubMed ID: 35273620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY
    Kyuuma M; Kaku A; Mishima-Tsumagari C; Ogawa B; Endo M; Tamura Y; Ishikura KI; Mima M; Nakanishi Y; Fujii Y
    Front Immunol; 2023; 14():1149874. PubMed ID: 37122706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis.
    Takeuchi T; Kawanishi M; Nakanishi M; Yamasaki H; Tanaka Y
    Arthritis Rheumatol; 2022 Nov; 74(11):1776-1785. PubMed ID: 35729713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of anti-TNF multivalent NANOBODY® compound 'ozoralizumab' without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial).
    Tanaka Y; Kawanishi M; Nakanishi M; Yamasaki H; Takeuchi T
    Mod Rheumatol; 2023 Aug; 33(5):875-882. PubMed ID: 36201360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial).
    Tanaka Y; Kawanishi M; Nakanishi M; Yamasaki H; Takeuchi T
    Mod Rheumatol; 2023 Aug; 33(5):883-890. PubMed ID: 36197757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis.
    Oyama S; Ebina K; Etani Y; Hirao M; Kyuuma M; Fujii Y; Iwata K; Ogawa B; Hasegawa T; Kawano S; Nakanishi Y; Okada S; Nakata K
    Sci Rep; 2022 Oct; 12(1):18102. PubMed ID: 36302840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate.
    Varani K; Massara A; Vincenzi F; Tosi A; Padovan M; Trotta F; Borea PA
    Arthritis Rheum; 2009 Oct; 60(10):2880-91. PubMed ID: 19790066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.
    Barrera P; Joosten LA; den Broeder AA; van de Putte LB; van Riel PL; van den Berg WB
    Ann Rheum Dis; 2001 Jul; 60(7):660-9. PubMed ID: 11406520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis.
    Baldwin HM; Ito-Ihara T; Isaacs JD; Hilkens CM
    Ann Rheum Dis; 2010 Jun; 69(6):1200-7. PubMed ID: 19773288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How does infliximab work in rheumatoid arthritis?
    Maini RN; Feldmann M
    Arthritis Res; 2002; 4 Suppl 2(Suppl 2):S22-8. PubMed ID: 12110154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour necrosis factor-alpha as a new therapeutic target for rheumatoid arthritis: an update.
    Giasuddin AS; Hoque ME; Ahmed ZU
    Bangladesh Med Res Counc Bull; 2005 Dec; 31(3):88-94. PubMed ID: 17549869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
    Harrison MJ; Dixon WG; Watson KD; King Y; Groves R; Hyrich KL; Symmons DP; ;
    Ann Rheum Dis; 2009 Feb; 68(2):209-15. PubMed ID: 18385277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased prevalence of allergic sensitisation in rheumatoid arthritis patients treated with anti-TNFalpha.
    Machado P; Santos A; Pereira C; Loureiro C; Silva J; Chieira C; Malcata A
    Joint Bone Spine; 2009 Oct; 76(5):508-13. PubMed ID: 19467899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.
    Koike R; Takeuchi T; Eguchi K; Miyasaka N;
    Mod Rheumatol; 2007; 17(6):451-8. PubMed ID: 18084695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
    Manadan AM; Block JA
    Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].
    Hirohata S
    Nihon Rinsho; 2007 Jul; 65(7):1202-8. PubMed ID: 17642233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis.
    Chovel-Sella A; Karplus R; Sella T; Amital H
    Isr Med Assoc J; 2012 Jun; 14(6):390-4. PubMed ID: 22891404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.